Tumor Immunotherapy Market - Global Outlook and Forecast 2022-2028

March 2022 | 116 pages | ID: TFECA19BDAD6EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Tumor Immunotherapy in Global, including the following market information:

Global Tumor Immunotherapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Tumor Immunotherapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Tumor Infiltrating Lymphocyte (TIL) Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Tumor Immunotherapy include Roche, Merck, Novartis, Johnson & Johnson, GlaxoSmithKline, AbbVie, ELI Lilly, Amgen and AstraZeneca, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tumor Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Tumor Immunotherapy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Tumor Immunotherapy Market Segment Percentages, by Type, 2021 (%)

• Tumor Infiltrating Lymphocyte (TIL) Treatment
• Engineered T Cell Receptor (TCR) Therapy
• Chimeric Antigen Receptor (CAR) T Cell Therapy
• Natural Killer (NK) Cell Therapy
• Other

Global Tumor Immunotherapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Tumor Immunotherapy Market Segment Percentages, by Application, 2021 (%)

• Biopharmaceutical Company
• Hospital
• Universities And Other Scientific Research Institutions
• Other

Global Tumor Immunotherapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Tumor Immunotherapy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Tumor Immunotherapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Tumor Immunotherapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Roche
• Merck
• Novartis
• Johnson & Johnson
• GlaxoSmithKline
• AbbVie
• ELI Lilly
• Amgen
• AstraZeneca
• Bristol-Mysers Squibb
• Kite Pharma
• Adaptimmune
• Altor Bioscience Corporation
• Cellectis
• Juno Therapeutics
• Takara Bio
• Unum Therapeutics
• Sunway
• Junshi Bio
• Cinda Bio
• BeiGene

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Tumor Immunotherapy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Tumor Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL TUMOR IMMUNOTHERAPY OVERALL MARKET SIZE

2.1 Global Tumor Immunotherapy Market Size: 2021 VS 2028
2.2 Global Tumor Immunotherapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Tumor Immunotherapy Players in Global Market
3.2 Top Global Tumor Immunotherapy Companies Ranked by Revenue
3.3 Global Tumor Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 Tumor Immunotherapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Tumor Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Tumor Immunotherapy Players in Global Market
  3.6.1 List of Global Tier 1 Tumor Immunotherapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Tumor Immunotherapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Tumor Immunotherapy Market Size Markets, 2021 & 2028
  4.1.2 Tumor Infiltrating Lymphocyte (TIL) Treatment
  4.1.3 Engineered T Cell Receptor (TCR) Therapy
  4.1.4 Chimeric Antigen Receptor (CAR) T Cell Therapy
  4.1.5 Natural Killer (NK) Cell Therapy
  4.1.6 Other
4.2 By Type - Global Tumor Immunotherapy Revenue & Forecasts
  4.2.1 By Type - Global Tumor Immunotherapy Revenue, 2017-2022
  4.2.2 By Type - Global Tumor Immunotherapy Revenue, 2023-2028
  4.2.3 By Type - Global Tumor Immunotherapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Tumor Immunotherapy Market Size, 2021 & 2028
  5.1.2 Biopharmaceutical Company
  5.1.3 Hospital
  5.1.4 Universities And Other Scientific Research Institutions
  5.1.5 Other
5.2 By Application - Global Tumor Immunotherapy Revenue & Forecasts
  5.2.1 By Application - Global Tumor Immunotherapy Revenue, 2017-2022
  5.2.2 By Application - Global Tumor Immunotherapy Revenue, 2023-2028
  5.2.3 By Application - Global Tumor Immunotherapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Tumor Immunotherapy Market Size, 2021 & 2028
6.2 By Region - Global Tumor Immunotherapy Revenue & Forecasts
  6.2.1 By Region - Global Tumor Immunotherapy Revenue, 2017-2022
  6.2.2 By Region - Global Tumor Immunotherapy Revenue, 2023-2028
  6.2.3 By Region - Global Tumor Immunotherapy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Tumor Immunotherapy Revenue, 2017-2028
  6.3.2 US Tumor Immunotherapy Market Size, 2017-2028
  6.3.3 Canada Tumor Immunotherapy Market Size, 2017-2028
  6.3.4 Mexico Tumor Immunotherapy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Tumor Immunotherapy Revenue, 2017-2028
  6.4.2 Germany Tumor Immunotherapy Market Size, 2017-2028
  6.4.3 France Tumor Immunotherapy Market Size, 2017-2028
  6.4.4 U.K. Tumor Immunotherapy Market Size, 2017-2028
  6.4.5 Italy Tumor Immunotherapy Market Size, 2017-2028
  6.4.6 Russia Tumor Immunotherapy Market Size, 2017-2028
  6.4.7 Nordic Countries Tumor Immunotherapy Market Size, 2017-2028
  6.4.8 Benelux Tumor Immunotherapy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Tumor Immunotherapy Revenue, 2017-2028
  6.5.2 China Tumor Immunotherapy Market Size, 2017-2028
  6.5.3 Japan Tumor Immunotherapy Market Size, 2017-2028
  6.5.4 South Korea Tumor Immunotherapy Market Size, 2017-2028
  6.5.5 Southeast Asia Tumor Immunotherapy Market Size, 2017-2028
  6.5.6 India Tumor Immunotherapy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Tumor Immunotherapy Revenue, 2017-2028
  6.6.2 Brazil Tumor Immunotherapy Market Size, 2017-2028
  6.6.3 Argentina Tumor Immunotherapy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Tumor Immunotherapy Revenue, 2017-2028
  6.7.2 Turkey Tumor Immunotherapy Market Size, 2017-2028
  6.7.3 Israel Tumor Immunotherapy Market Size, 2017-2028
  6.7.4 Saudi Arabia Tumor Immunotherapy Market Size, 2017-2028
  6.7.5 UAE Tumor Immunotherapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Roche
  7.1.1 Roche Corporate Summary
  7.1.2 Roche Business Overview
  7.1.3 Roche Tumor Immunotherapy Major Product Offerings
  7.1.4 Roche Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.1.5 Roche Key News
7.2 Merck
  7.2.1 Merck Corporate Summary
  7.2.2 Merck Business Overview
  7.2.3 Merck Tumor Immunotherapy Major Product Offerings
  7.2.4 Merck Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.2.5 Merck Key News
7.3 Novartis
  7.3.1 Novartis Corporate Summary
  7.3.2 Novartis Business Overview
  7.3.3 Novartis Tumor Immunotherapy Major Product Offerings
  7.3.4 Novartis Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.3.5 Novartis Key News
7.4 Johnson & Johnson
  7.4.1 Johnson & Johnson Corporate Summary
  7.4.2 Johnson & Johnson Business Overview
  7.4.3 Johnson & Johnson Tumor Immunotherapy Major Product Offerings
  7.4.4 Johnson & Johnson Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.4.5 Johnson & Johnson Key News
7.5 GlaxoSmithKline
  7.5.1 GlaxoSmithKline Corporate Summary
  7.5.2 GlaxoSmithKline Business Overview
  7.5.3 GlaxoSmithKline Tumor Immunotherapy Major Product Offerings
  7.5.4 GlaxoSmithKline Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.5.5 GlaxoSmithKline Key News
7.6 AbbVie
  7.6.1 AbbVie Corporate Summary
  7.6.2 AbbVie Business Overview
  7.6.3 AbbVie Tumor Immunotherapy Major Product Offerings
  7.6.4 AbbVie Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.6.5 AbbVie Key News
7.7 ELI Lilly
  7.7.1 ELI Lilly Corporate Summary
  7.7.2 ELI Lilly Business Overview
  7.7.3 ELI Lilly Tumor Immunotherapy Major Product Offerings
  7.7.4 ELI Lilly Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.7.5 ELI Lilly Key News
7.8 Amgen
  7.8.1 Amgen Corporate Summary
  7.8.2 Amgen Business Overview
  7.8.3 Amgen Tumor Immunotherapy Major Product Offerings
  7.8.4 Amgen Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.8.5 Amgen Key News
7.9 AstraZeneca
  7.9.1 AstraZeneca Corporate Summary
  7.9.2 AstraZeneca Business Overview
  7.9.3 AstraZeneca Tumor Immunotherapy Major Product Offerings
  7.9.4 AstraZeneca Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.9.5 AstraZeneca Key News
7.10 Bristol-Mysers Squibb
  7.10.1 Bristol-Mysers Squibb Corporate Summary
  7.10.2 Bristol-Mysers Squibb Business Overview
  7.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Major Product Offerings
  7.10.4 Bristol-Mysers Squibb Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.10.5 Bristol-Mysers Squibb Key News
7.11 Kite Pharma
  7.11.1 Kite Pharma Corporate Summary
  7.11.2 Kite Pharma Business Overview
  7.11.3 Kite Pharma Tumor Immunotherapy Major Product Offerings
  7.11.4 Kite Pharma Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.11.5 Kite Pharma Key News
7.12 Adaptimmune
  7.12.1 Adaptimmune Corporate Summary
  7.12.2 Adaptimmune Business Overview
  7.12.3 Adaptimmune Tumor Immunotherapy Major Product Offerings
  7.12.4 Adaptimmune Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.12.5 Adaptimmune Key News
7.13 Altor Bioscience Corporation
  7.13.1 Altor Bioscience Corporation Corporate Summary
  7.13.2 Altor Bioscience Corporation Business Overview
  7.13.3 Altor Bioscience Corporation Tumor Immunotherapy Major Product Offerings
  7.13.4 Altor Bioscience Corporation Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.13.5 Altor Bioscience Corporation Key News
7.14 Cellectis
  7.14.1 Cellectis Corporate Summary
  7.14.2 Cellectis Business Overview
  7.14.3 Cellectis Tumor Immunotherapy Major Product Offerings
  7.14.4 Cellectis Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.14.5 Cellectis Key News
7.15 Juno Therapeutics
  7.15.1 Juno Therapeutics Corporate Summary
  7.15.2 Juno Therapeutics Business Overview
  7.15.3 Juno Therapeutics Tumor Immunotherapy Major Product Offerings
  7.15.4 Juno Therapeutics Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.15.5 Juno Therapeutics Key News
7.16 Takara Bio
  7.16.1 Takara Bio Corporate Summary
  7.16.2 Takara Bio Business Overview
  7.16.3 Takara Bio Tumor Immunotherapy Major Product Offerings
  7.16.4 Takara Bio Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.16.5 Takara Bio Key News
7.17 Unum Therapeutics
  7.17.1 Unum Therapeutics Corporate Summary
  7.17.2 Unum Therapeutics Business Overview
  7.17.3 Unum Therapeutics Tumor Immunotherapy Major Product Offerings
  7.17.4 Unum Therapeutics Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.17.5 Unum Therapeutics Key News
7.18 Sunway
  7.18.1 Sunway Corporate Summary
  7.18.2 Sunway Business Overview
  7.18.3 Sunway Tumor Immunotherapy Major Product Offerings
  7.18.4 Sunway Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.18.5 Sunway Key News
7.19 Junshi Bio
  7.19.1 Junshi Bio Corporate Summary
  7.19.2 Junshi Bio Business Overview
  7.19.3 Junshi Bio Tumor Immunotherapy Major Product Offerings
  7.19.4 Junshi Bio Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.19.5 Junshi Bio Key News
7.20 Cinda Bio
  7.20.1 Cinda Bio Corporate Summary
  7.20.2 Cinda Bio Business Overview
  7.20.3 Cinda Bio Tumor Immunotherapy Major Product Offerings
  7.20.4 Cinda Bio Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.20.5 Cinda Bio Key News
7.21 BeiGene
  7.21.1 BeiGene Corporate Summary
  7.21.2 BeiGene Business Overview
  7.21.3 BeiGene Tumor Immunotherapy Major Product Offerings
  7.21.4 BeiGene Tumor Immunotherapy Revenue in Global Market (2017-2022)
  7.21.5 BeiGene Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Tumor Immunotherapy Market Opportunities & Trends in Global Market
Table 2. Tumor Immunotherapy Market Drivers in Global Market
Table 3. Tumor Immunotherapy Market Restraints in Global Market
Table 4. Key Players of Tumor Immunotherapy in Global Market
Table 5. Top Tumor Immunotherapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Tumor Immunotherapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Tumor Immunotherapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Tumor Immunotherapy Product Type
Table 9. List of Global Tier 1 Tumor Immunotherapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Tumor Immunotherapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Tumor Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Tumor Immunotherapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Tumor Immunotherapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Tumor Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Tumor Immunotherapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Tumor Immunotherapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Tumor Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Tumor Immunotherapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Tumor Immunotherapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Tumor Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Tumor Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Tumor Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Tumor Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Tumor Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Tumor Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Tumor Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Tumor Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Tumor Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Tumor Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 30. Roche Corporate Summary
Table 31. Roche Tumor Immunotherapy Product Offerings
Table 32. Roche Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 33. Merck Corporate Summary
Table 34. Merck Tumor Immunotherapy Product Offerings
Table 35. Merck Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Tumor Immunotherapy Product Offerings
Table 38. Novartis Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 39. Johnson & Johnson Corporate Summary
Table 40. Johnson & Johnson Tumor Immunotherapy Product Offerings
Table 41. Johnson & Johnson Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 42. GlaxoSmithKline Corporate Summary
Table 43. GlaxoSmithKline Tumor Immunotherapy Product Offerings
Table 44. GlaxoSmithKline Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 45. AbbVie Corporate Summary
Table 46. AbbVie Tumor Immunotherapy Product Offerings
Table 47. AbbVie Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 48. ELI Lilly Corporate Summary
Table 49. ELI Lilly Tumor Immunotherapy Product Offerings
Table 50. ELI Lilly Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 51. Amgen Corporate Summary
Table 52. Amgen Tumor Immunotherapy Product Offerings
Table 53. Amgen Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 54. AstraZeneca Corporate Summary
Table 55. AstraZeneca Tumor Immunotherapy Product Offerings
Table 56. AstraZeneca Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 57. Bristol-Mysers Squibb Corporate Summary
Table 58. Bristol-Mysers Squibb Tumor Immunotherapy Product Offerings
Table 59. Bristol-Mysers Squibb Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 60. Kite Pharma Corporate Summary
Table 61. Kite Pharma Tumor Immunotherapy Product Offerings
Table 62. Kite Pharma Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 63. Adaptimmune Corporate Summary
Table 64. Adaptimmune Tumor Immunotherapy Product Offerings
Table 65. Adaptimmune Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 66. Altor Bioscience Corporation Corporate Summary
Table 67. Altor Bioscience Corporation Tumor Immunotherapy Product Offerings
Table 68. Altor Bioscience Corporation Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 69. Cellectis Corporate Summary
Table 70. Cellectis Tumor Immunotherapy Product Offerings
Table 71. Cellectis Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 72. Juno Therapeutics Corporate Summary
Table 73. Juno Therapeutics Tumor Immunotherapy Product Offerings
Table 74. Juno Therapeutics Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 75. Takara Bio Corporate Summary
Table 76. Takara Bio Tumor Immunotherapy Product Offerings
Table 77. Takara Bio Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 78. Unum Therapeutics Corporate Summary
Table 79. Unum Therapeutics Tumor Immunotherapy Product Offerings
Table 80. Unum Therapeutics Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 81. Sunway Corporate Summary
Table 82. Sunway Tumor Immunotherapy Product Offerings
Table 83. Sunway Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 84. Junshi Bio Corporate Summary
Table 85. Junshi Bio Tumor Immunotherapy Product Offerings
Table 86. Junshi Bio Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 87. Cinda Bio Corporate Summary
Table 88. Cinda Bio Tumor Immunotherapy Product Offerings
Table 89. Cinda Bio Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 90. BeiGene Corporate Summary
Table 91. BeiGene Tumor Immunotherapy Product Offerings
Table 92. BeiGene Tumor Immunotherapy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Tumor Immunotherapy Segment by Type in 2021
Figure 2. Tumor Immunotherapy Segment by Application in 2021
Figure 3. Global Tumor Immunotherapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Tumor Immunotherapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Tumor Immunotherapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Tumor Immunotherapy Revenue in 2021
Figure 8. By Type - Global Tumor Immunotherapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Tumor Immunotherapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Tumor Immunotherapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Tumor Immunotherapy Revenue Market Share, 2017-2028
Figure 12. US Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Tumor Immunotherapy Revenue Market Share, 2017-2028
Figure 16. Germany Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 17. France Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Tumor Immunotherapy Revenue Market Share, 2017-2028
Figure 24. China Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 28. India Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Tumor Immunotherapy Revenue Market Share, 2017-2028
Figure 30. Brazil Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Tumor Immunotherapy Revenue Market Share, 2017-2028
Figure 33. Turkey Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Tumor Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 37. Roche Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Merck Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Johnson & Johnson Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GlaxoSmithKline Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. AbbVie Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. ELI Lilly Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Amgen Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. AstraZeneca Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Bristol-Mysers Squibb Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Kite Pharma Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Adaptimmune Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Altor Bioscience Corporation Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Cellectis Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Juno Therapeutics Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Takara Bio Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Unum Therapeutics Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Sunway Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Junshi Bio Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Cinda Bio Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 57. BeiGene Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)